🧾 What This Document Is

This is a 6-K filing from Nanobiotix, which is a current report foreign companies file with the SEC to share major news. It contains a press release that serves as a comprehensive business update and a report of their full financial results for 2025. Think of it as the company's annual "state of the union" for investors, explaining what they did, how they're funded, and where they're headed.

🏢 What The Company Does

👉 In simple terms, Nanobiotix is a biotech company inventing tiny particles to help treat cancer.

They are a "late-clinical stage" company, meaning their lead product is in advanced testing with patients. Their main technology platform involves nanoparticles designed to be injected into a tumor and then activated by standard radiotherapy (radiation). This process is intended to boost the cancer-killing power of the radiation and potentially trigger the body's immune system to fight the cancer long-term. They are publicly traded in both Paris (Euronext: NANO) and on the Nasdaq in the US (NBTX).

🧪 The Clinical Program Deep Dive

This section is the heart of the update. Nanobiotix's lead product, JNJ-1900 (NBTXR3), is being developed in a global partnership with Johnson & Johnson. Here’s what’s happening:

Lead Programs Pivoting to J&J: Two major Phase 3 studies are underway.
1. Head & Neck Cancer (NANORAY-312): This is the most advanced study. A key milestone was reached in late 2025: sponsorship of the trial was fully transferred to Janssen (J&J). This is a big deal—it means the pharmaceutical giant is now fully running and funding this pivotal trial.
2. Lung Cancer (CONVERGE): The first patient was dosed in this study in early 2025, and initial data was presented in early 2026.
Broad Early-Stage Data Released: The company presented promising early-stage clinical data from several smaller studies, suggesting the drug's potential beyond head and neck cancer:
- Esophageal Cancer: Showed a 69% objective response rate in 13 patients.
- Pancreatic Cancer: In 22 patients, the median overall survival was 23 months from diagnosis, which is encouraging for this difficult cancer.
- Lung Cancer (Re-irradiation): In 12 patients, 64% were progression-free at 12 months.
- Melanoma & Head & Neck (Recurrent): Showed activity in patients who had already failed other treatments like immunotherapy.

👉 Why it matters: The data, while from early-phase studies, paints a picture of a potentially versatile cancer treatment that works across different tumor types when combined with radiation. The successful transfer of the lead trial to J&J validates the partnership.

💰 Financial Highlights

Let's break down the money in simple terms.

Revenue & Loss: The company reported €32.6 million in total revenue for 2025, a huge swing from a negative €7.2 million in 2024. This wasn't from selling a drug, but from complex accounting related to their deal amendment with J&J. Their net loss shrank dramatically to €24.0 million from €68.1 million the prior year.
Spending: Research & Development (R&D) costs fell by 43% to €23.1 million, mainly because they no longer have to pay for the big J&J-led head & neck cancer trial. General & Admin costs were stable at €20.4 million.
Cash is King: As of December 31, 2025, Nanobiotix had €52.8 million in cash. Crucially, they state this cash will fund operations into early 2028.

💸 The Big Financing Move

This is a critical strategic move that explains their long cash runway.

In late 2025, they completed a $71 million royalty financing deal with HealthCare Royalty (HCRx). They received $50 million upfront in December 2025.
This is "non-dilutive" financing. That means they didn't have to sell new shares (which dilutes existing shareholders). Instead, they sold a portion of future royalties (payments) they might receive from future sales of their drug.
The remaining $21 million is expected about a year later, once certain conditions are met.

👉 Why it matters: This deal provided a large cash injection without giving up ownership, directly leading to their extended financial runway into 2028. It de-risks the company's near-term survival while they wait for potential drug approvals and future milestone payments.

🔮 What's Next

The company has a clear and busy roadmap for 2026 and beyond:

Clinical Data is Due: Multiple important data readouts are expected in 2026 from early-stage studies in non-small cell lung cancer (NSCLC), pancreatic cancer, melanoma, and esophageal cancer.
Supporting J&J: They will continue to support Johnson & Johnson as the lead programs in head and neck cancer (NANORAY-312) and lung cancer (CONVERGE) advance.
Growing the Next Platform: A big focus for internal growth is their Curadigm Nanoprimer platform. This is a separate technology aimed at improving how drugs are delivered. In 2025, they filed four new patents, launched manufacturing activities, and are building external collaborations. This represents the "next wave" of potential products.

⚖️ The Big Picture

👍 Strengths:

A deep, validating partnership with a pharmaceutical giant (J&J).
A strong portfolio of early clinical data showing potential across many cancers.
A fortified, non-dilutive financial position with a runway into 2028.
A next-generation platform (Nanoprimer) with its own momentum, providing a pipeline beyond the lead product.

⚠️ Risks:

The lead product, JNJ-1900, is still investigational and not approved. The ongoing Phase 3 trials must succeed.
The company is still loss-making and not yet self-sustaining from commercial revenue.
Future funding partly depends on receiving the remaining $21 million from the HCRx deal and on securing future partnerships or milestone payments.
They operate in the highly competitive and risky field of oncology drug development.

🧠 The Analogy

Imagine Nanobiotix is a skilled engineering company that invented a powerful "turbo-booster" for existing engines (radiation). They've licensed this turbo technology to a major car manufacturer (J&J) to install in their flagship race cars (the head & neck and lung cancer trials). Meanwhile, they're also testing the turbo in other vehicles (esophageal, pancreatic cancers) and, in their own garage, are busy building a completely new type of high-efficiency fuel injector (the Nanoprimer platform) for future engines. Their recent financing gave them enough fuel to keep both workshops running for years to come, even before the first turbo-boosted car wins a race (drug approval).

📇 Key Contacts & People

Laurent Levy, Co-founder, Chairman of the Executive Board, and CEO.
Bart Van Rhijn, Chief Financial and Business Officer.
Brandon Owens, VP, Communications. Contact: +1 (617) 852-4835, [email protected]
Joanne Choi, VP, Investor Relations (US). Contact: +1 (713) 609-3150, [email protected]
Ricky Bhajun, Director, Investor Relations (EU). Contact: +33 (0) 79 97 29 99, [email protected]
Caroline Hardy, Media Relations (France). Contact: +33 (0)6 70 33 49 50, [email protected]
Becky Lauer, Global Media Relations (uncapped). Contact: +1 (646) 286-0057, [email protected]

🧩 Final Takeaway

Nanobiotix successfully de-risked its financials through a clever $71M non-dilutive financing, buying itself time into 2028. The company's core technology continues to show promising early signs of working across many cancer types, with a powerful partner (J&J) now driving the pivotal trials. 2026 will be a data-rich year that could significantly validate the science.

Nanobiotix S.A. — 6-K Filing